2-hydroxypropanimidamide hydrochloride | 89799-34-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-hydroxypropanimidamide hydrochloride
• 英文别名: 2-hydroxypropanimidamide;hydrochloride
• CAS: 89799-34-8
• 化学式: C₃H₈N₂O*ClH
• mdl: MFCD26937570
• 分子量: 124.57
• InChiKey: AEOZCEMLLBCHQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.21
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  70.1
• 氢给体数：
  4
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-hydroxypropanimidamide hydrochloride 、 N-氰亚胺基-S,S-二硫代碳酸二甲酯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 18.0h， 生成 1-(4-amino-6-(methylthio)-1,3,5-triazin-2-yl)ethanol
  参考文献：
  名称：

  [EN] AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS
  [FR] DÉRIVÉS AMINO-HÉTÉROARYLE EN TANT QUE COMPOSÉS BLOQUANT HCN

  摘要：

  这项发明涉及具有一般化学式I或其药用可接受盐的氨基-杂环芳基衍生物，以及包含这些衍生物的药物组合物，以及利用这些衍生物治疗疼痛，如神经病性疼痛或炎症性疼痛。

  公开号：

  WO2011076723A1
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 氨 作用下， 生成 2-hydroxypropanimidamide hydrochloride
  参考文献：
  名称：

  Klarer; Urech, Helvetica Chimica Acta, 1944, vol. 27, p. 1768

  摘要：

  DOI：

文献信息

• [EN] TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS<br/>[FR] INHIBITEURS TRICYCLIQUES DE GYRASE UTILISABLES COMME AGENTS ANTIBACTÉRIENS
  申请人：TRIUS THERAPEUTICS INC

  公开号：WO2014043272A1

  公开（公告）日：2014-03-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. In addition, species of tricyclic gyrase inhibitors compounds are also disclosed herein. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有化学式I结构的化合物及其药用盐、酯和前药，这些化合物可用作抗菌有效的三环酶抑制剂。此外，本文还披露了三环酶抑制剂化合物的种属。还考虑了相关的药用组合物、用途和制备这些化合物的方法。
• TNF -Alpha Modulating Benzimidazoles
  申请人：UCB Biopharma SPRL

  公开号：US20150152065A1

  公开（公告）日：2015-06-04

  A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

  一系列苯并咪唑衍生物，作为人类肿瘤坏死因子α活性的强效调节剂，因此在治疗和/或预防各种人类疾病方面具有益处，包括自身免疫和炎症性疾病；神经和神经退行性疾病；疼痛和痛觉障碍；心血管疾病；代谢性疾病；眼科疾病；以及肿瘤学疾病。
• Compounds for treating and preventing diabetic complications
  申请人：Pfizer Inc.

  公开号：US06294538B1

  公开（公告）日：2001-09-25

  This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R is as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

  这项发明涉及式I的山梨醇脱氢酶抑制化合物，其中R如规范中所定义。这项发明还涉及含有这些化合物的药物组合物，以及通过向患有糖尿病且因此有发生这些并发症风险的哺乳动物施用这些化合物来治疗或预防糖尿病并发症，特别是糖尿病神经病变、糖尿病肾病和糖尿病心肌病。这项发明还涉及含有本发明式I化合物与醛糖还原酶抑制剂的组合物的药物组合物，以及用于治疗或预防糖尿病并发症的方法。这项发明还涉及含有本发明式I化合物与NHE-1抑制剂的组合物的药物组合物，以及用于治疗心肌病和其他心脏相关问题的方法。这项发明还涉及用于合成式I化合物的某些中间体以及制备这些中间体的方法。
• TRICYCLIC GYRASE INHIBITORS
  申请人：Bensen Daniel

  公开号：US20120238751A1

  公开（公告）日：2012-09-20

  Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.

  本文披露了具有式I结构的化合物，以及作为抗菌有效的三环酶抑制剂的药用盐、酯和前药，相关的药物组合物、用途和制备该化合物的方法也在考虑之中。
• [EN] HYDROXYALKYL-SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE TRIAZOLE SUBSTITUÉS PAR HYDROXYALKYLE ET UTILISATIONS ASSOCIÉES
  申请人：BAYER PHARMA AG

  公开号：WO2018073144A1

  公开（公告）日：2018-04-26

  The present invention relates to novel 3-(hydroxyalkyl)-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and/or cardiovascular diseases.

  本发明涉及新颖的3-(羟基烷基)-1,2,4-三唑衍生物，涉及制备这类化合物的方法，涉及含有这类化合物的药物组合物，以及涉及利用这类化合物或组合物治疗和/或预防疾病，特别是治疗和/或预防肾脏和/或心血管疾病。